D
dananumab
Productby Eli Lilly and Company
Heard in 2 episodes across 2 shows since Sep 2026
Donanemab is an anti-amyloid monoclonal antibody for early Alzheimer’s disease that targets deposited amyloid plaques; it was developed by Eli Lilly and marketed as Kisunla.
Episodes
2
across 2 shows
First heard
Sep 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
2
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 2 |
| Oct 2026 | 0 |
Episodes
2 episodes featuring dananumab, newest first
